Regulacje i polityka gospodarcza · 23/11/2007

Public Teleconference to Discuss Licensing and Collaboration Opportunities for BORIS, a Novel Protein for Cancer Diagnosis and Treatment, with Dr. Victor Lobanenkov and NIAID

The National Institute of Allergy and Infectious Diseases (NIAID) is hosting a public teleconference to explore licensing and collaborative research opportunities for BORIS, a novel protein that may be used for cancer diagnosis and as a therapeutic target for treating several types of cancer, led by Dr. Victor Lobanenkov.